ATHA Athira Pharma, Inc. Stock Quote

ATHA [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	0.40%	Shs Outstand	35.78M	Perf Week	-1.50%
Market Cap	739.14M	Forward P/E	-	EPS next Y	-2.09	Insider Trans	207.30%	Shs Float	35.51M	Perf Month	9.44%
Income	-	PEG	-	EPS next Q	-0.34	Inst Own	70.90%	Short Float	3.90%	Perf Quarter	-8.63%
Sales	-	P/S	-	EPS this Y	-915.40%	Inst Trans	22.08%	Short Ratio	4.47	Perf Half Y	-24.49%
Book/sh	10.15	P/B	1.94	EPS next Y	-22.00%	ROA	-	Target Price	-	Perf Year	-
Cash/sh	8.11	P/C	2.43	EPS next 5Y	-	ROE	-	52W Range	15.79 - 34.79	Perf YTD	-42.48%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-43.14%	Beta	-
Dividend %	-	Quick Ratio	69.30	Sales past 5Y	-	Gross Margin	-	52W Low	25.27%	ATR	1.31
Employees	20	Current Ratio	69.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	54.15	Volatility	8.95% 6.81%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-50.90%	Profit Margin	-	Rel Volume	0.59	Prev Close	19.70
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	310.04K	Price	19.78
Recom	1.50	SMA20	3.20%	SMA50	6.45%	SMA200	-7.49%	Volume	60,362	Change	0.41%

Oct-13-20

Initiated

Stifel

Buy

$36

Oct-13-20

Initiated

JMP Securities

Mkt Outperform

$51

Oct-13-20

Initiated

Jefferies

Buy

$30

Oct-13-20

Initiated

Goldman

Buy

$53

Jun-14-21 07:00AM	Athira Pharma Appoints Rachel Lenington as Chief Technology Officer, Head of Product Development Strategy GlobeNewswire
Jun-09-21 07:00AM	Athira Pharma to Present at Upcoming Investor Conferences GlobeNewswire
Jun-01-21 07:00AM	Athira Pharma Appoints Mark Worthington as General Counsel GlobeNewswire -5.42%
May-26-21 07:00AM	Athira Pharma to Present at Upcoming Investor Conferences GlobeNewswire
May-21-21 04:08PM	The Fight Against Alzheimer's Reaches A Moment Of Truth For Biogen, Other Biotech Stocks Investor's Business Daily
May-13-21 04:02PM	Athira Pharma Reports First Quarter 2021 Financial Results and Provides Business Highlights GlobeNewswire
Apr-22-21 12:00PM	Athira Pharma, Inc. (ATHA) Upgraded to Buy: Here's What You Should Know Zacks
Apr-21-21 07:00AM	Athira Pharma to Participate in Panel Discussion at Sachs 4th Annual Neuroscience Innovation Forum GlobeNewswire
Apr-08-21 07:00AM	Athira Pharma to Host Educational Webinar on Targeting HGF/MET: A Naturally Occurring Neuronal Repair Pathway GlobeNewswire
Mar-25-21 04:02PM	Athira Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights GlobeNewswire
Mar-24-21 07:00AM	Athira Pharma to Present at Stifels 3rd Annual CNS Conference GlobeNewswire
Mar-23-21 07:00AM	Athira Pharma to Participate in Panel and Corporate Presentations at Life Science Innovation Northwest Conference GlobeNewswire
Mar-18-21 01:36AM	Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth Simply Wall St.
Mar-08-21 07:00AM	Athira Pharma Announces Appointment of Barbara Kosacz to its Board of Directors GlobeNewswire
Mar-02-21 07:00AM	Athira Pharma to Present at H.C. Wainwright & Co. Global Life Sciences Conference GlobeNewswire
Feb-10-21 04:05PM	Athira Pharma Announces Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -7.22%
Jan-21-21 05:50PM	Why Athira Pharma Stock Dropped Today Motley Fool -16.65%
Jan-20-21 07:35PM	Athira Pharma Announces Pricing of Public Offering of Common Stock GlobeNewswire -6.06%
Jan-19-21 07:59AM	Athira Pharma Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-07-21 07:30AM	Athira Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-18-20 09:17PM	Is ATHA A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-17-20 11:49PM	What Type Of Shareholders Make Up Athira Pharma, Inc.'s (NASDAQ:ATHA) Share Registry? Simply Wall St. +5.76%
Dec-14-20 07:30AM	Athira Pharma Announces Appointment of Kelly A. Romano to its Board of Directors GlobeNewswire
Dec-08-20 07:30AM	Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimers Disease GlobeNewswire
Dec-01-20 07:30AM	Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimers Disease GlobeNewswire
Nov-12-20 04:05PM	Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights GlobeNewswire +5.06%
Nov-10-20 07:30AM	Athira Pharma to Present at Upcoming November Investor Conferences GlobeNewswire
Oct-21-20 07:30AM	Athira Pharma to Host Educational Webinar on the Predictive Nature of P300 to Determine Clinical Benefit of Alzheimers Disease Treatments GlobeNewswire
Oct-18-20 11:00AM	Goldman Sachs: 2 Stocks That Could Climb Over 90% TipRanks
Oct-08-20 07:30AM	Lumen Bioscience Announces Appointment of Dr. Mark Litton to Board of Directors PR Newswire
Oct-01-20 07:30AM	Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of Mild-to-Moderate Alzheimer's Disease GlobeNewswire -8.07%
Sep-22-20 04:05PM	Athira Pharma Announces Closing of Initial Public Offering GlobeNewswire
Sep-18-20 12:04PM	Athira Pharma's stock jumps at its open, with the first trade 17% above the IPO price MarketWatch
11:35AM	Athira Pharma CEO to Wall Street: there needs to be more support for diversification in people, founders Yahoo Finance Video
06:27AM	Athira Pharma prices upsized IPO at $17, high end of price range MarketWatch
Sep-17-20 08:21PM	Athira Pharma Announces Pricing of Initial Public Offering GlobeNewswire

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MILESON GLENNA	Chief Financial Officer	Jun 10	Option Exercise	1.35	6,305	8,512	89,824	Jun 10 06:48 PM
CHURCH KEVIN	Vice President of Discovery	Jun 08	Option Exercise	1.04	3,152	3,278	44,133	Jun 09 05:39 PM
FLUKE JOHN M JR	Director	Feb 03	Option Exercise	1.21	29,003	35,119	143,884	Feb 04 08:18 PM
PERCEPTIVE ADVISORS LLC	Director	Jan 25	Buy	22.50	311,111	6,999,998	3,425,916	Jan 27 05:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience